Role of Nanotrace Element in Prostate Cancer an Update

References (96)

1. 1 A clearer vision for in vivo imaging [DOI]
2. 2 The anti-angiogenic basis of metronomic chemotherapy [DOI]
3. 3 Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications [DOI]
4. 4 DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
5. 5 A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy [DOI]
6. 6 Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. [DOI]
7. 7 Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment [DOI]
8. 8 Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors [DOI]
9. 9 Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population [DOI]
10. 10 Zinc oxide nanoparticles induce apoptosis and autophagy in human ovarian cancer cells [DOI]
11. 11 Exosomes as Biomarker Treasure Chests for Prostate Cancer [DOI]
12. 12 Immunotherapy of Prostate Cancer: Facts and Hopes [DOI]
13. 13 A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer [DOI]
14. 14 Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells [DOI]
15. 15 New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy [DOI]
16. 16 Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer [DOI]
17. 17 Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation [DOI]
18. 18 Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error [DOI]
19. 19 Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers [DOI]
20. 20 A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. [DOI]
21. 21 Testosterone Therapy in Men With Prostate Cancer [DOI]
22. 22 Synthesis and Anticancer Properties of Water-Soluble Zinc Ionophores [DOI]
23. 23 Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis [DOI]
24. 24 Detection and characterisation of biopsy tissue using quantitative optical coherence elastography (OCE) in men with suspected prostate cancer [DOI]
25. 25 Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel [DOI]
26. 26 Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer [DOI]
27. 27 Arsenic in Cancer Treatment: Challenges for Application of Realgar Nanoparticles (A Minireview) [DOI]
28. 28 Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer [DOI]
29. 29 Highlights of recent developments and trends in cancer nanotechnology research—View from NCI Alliance for Nanotechnology in Cancer [DOI]
30. 30 Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer [DOI]
31. 31 Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers [DOI]
32. 32 The role of mitochondria in the oncogenic signal transduction [DOI]
33. 33 Decreased expression of ferroportin in prostate cancer [DOI]
34. 34 Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS [DOI]
35. 35 Copper supplementation amplifies the anti-tumor effect of curcumin in oral cancer cells [DOI]
36. 36 Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway [DOI]
37. 37 New perspectives of cobalt tris(bipyridine) system: anti-cancer effect and its collateral sensitivity towards multidrug-resistant (MDR) cancers [DOI]
38. 38 China and the United States—Global partners, competitors and collaborators in nanotechnology development [DOI]
39. 39 A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer [DOI]
40. 40 Comparison of in Vitro Cytotoxicity and Apoptogenic Activity of Magnesium Chloride and Cisplatin as Conventional Chemotherapeutic Agents in the MCF-7 Cell Line [DOI]
41. 41 New serum biomarkers for prostate cancer diagnosis [DOI]
42. 42 Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience [DOI]
43. 43 Protective effect of selenium against cisplatin-induced nasopharyngeal cancer in male albino rats [DOI]
44. 44 Comparative Cytotoxicity Induced by Zinc Oxide Nanoparticles in Human Prostate Cells [DOI]
45. 45 Iodinated chlorin p6 copper complex induces anti-proliferative effect in oral cancer cells through elevation of intracellular reactive oxygen species [DOI]
46. 46 Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients.
47. 47 Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma [DOI]
48. 48 Radiation Therapy for Prostate Cancer [DOI]
49. 49 Histopathology of Prostate Cancer [DOI]
50. 50 Stereotactic body radiation therapy for prostate cancer—a review [DOI]
51. 51 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [DOI]
52. 52 Targeting Ferroptosis to Iron Out Cancer [DOI]
53. 53 Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates [DOI]
54. 54 Therapeutic applications of selenium nanoparticles [DOI]
55. 55 Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling [DOI]
56. 56 Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs [DOI]
57. 57 Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms [DOI]
58. 58 Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies [DOI]
59. 59 Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial [DOI]
60. 60 Role of chemotherapy in prostate cancer [DOI]
61. 61 Glycans as Biomarkers in Prostate Cancer [DOI]
62. 62 Biomolecular Interaction, Anti-Cancer and Anti-Angiogenic Properties of Cobalt(III) Schiff Base Complexes [DOI]
63. 63 T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer [DOI]
64. 64 Cisplatin enhances cell stiffness and decreases invasiveness rate in prostate cancer cells by actin accumulation [DOI]
65. 65 Long non-coding RNAs in prostate cancer: Functional roles and clinical implications [DOI]
66. 66 Plectin is a regulator of prostate cancer growth and metastasis [DOI]
67. 67 Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases [DOI]
68. 68 Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study [DOI]
69. 69 Evolution of Nanotechnology in Delivering Drugs to Eyes, Skin and Wounds via Topical Route [DOI]
70. 70 Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species [DOI]
71. 71 A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer [DOI]
72. 72 Albumin binding and anticancer effect of magnesium oxide nanoparticles [DOI]
73. 73 Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients [DOI]
74. 74 PSA targeted dual-modality manganese oxide–mesoporous silica nanoparticles for prostate cancer imaging [DOI]
75. 75 Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint [DOI]
76. 76 Hormonal treatment and quality of life of prostate cancer patients: new evidence [DOI]
77. 77 Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer [DOI]
78. 78 Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men [DOI]
79. 79 Steering Efficacy of Nano Molybdenum Towards Cancer: Mechanism of Action [DOI]
80. 80 Exploring the Interaction of Cobalt Oxide Nanoparticles with Albumin, Leukemia Cancer Cells and Pathogenic Bacterial by Multispectroscopic, Docking, Cellular and Antibacterial Approaches [DOI]
81. 81 Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients [DOI]
82. 82 Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation [DOI]
83. 83 Selenium Supplementation and Prostate Health in a New Zealand Cohort [DOI]
84. 84 The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer [DOI]
85. 85 Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics [DOI]
86. 86 Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review [DOI]
87. 87 Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo [DOI]
88. 88 Copper-64 Chloride Exhibits Therapeutic Potential in Three-Dimensional Cellular Models of Prostate Cancer [DOI]
89. 89 Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer [DOI]
90. 90 Anti-prostate cancer activity of 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide copper complexes in vivo by bioluminescence imaging [DOI]
91. 91 Analysis of trace elements in human hair through X-ray fluorescence spectroscopy for screening of prostate cancer. [DOI]
92. 92 Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer [DOI]
93. 93 ICP-MS analysis of diet supplementation influence on the elemental content of rat prostate gland [DOI]
94. 94 Antitumor Effect of Calcium-Mediated Destabilization of Epithelial Growth Factor Receptor on Non-Small Cell Lung Carcinoma [DOI]
95. 95 Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer [DOI]
96. 96 Clinical utility study of confirms mdx for prostate cancer in a community urology practice. [DOI]

Cited by 0

No indexed citations yet.

Related research

• Maternal Age and Congenital Anomalies among Newborns in a Tertiary Health Facility in Benue State, North Central Nigeria — shares topic coverage
• Early Diagnosis of Neonatal Sepsis: A Review of the Current Methods in Clinical Practice — shares topic coverage
• Skeletal Dysplasia: Approach to Simplify Diagnosis, Looking for Radiographic Clue Signs — shares topic coverage
• Impact of Radiology on the Early Identification of Waterhouse-friderichsen Syndrome: A Case Study — shares topic coverage
• The Impact of Genexpert MTB/RIF Technology on the Minimization of Tuberculosis: A Review of Literature — shares topic coverage